No Data
JMP Securities Maintains CureVac(CVAC.US) With Buy Rating, Maintains Target Price $16
CureVac's Promising Cancer Vaccine Candidate CVGBM Elicits Buy Rating
Express News | CureVac Shares Are Trading Higher After the Company Presented Its CVGBM Cancer Vaccine Results From Its Phase 1 Study of Glioblastoma at the ESMO 2024 Congress
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza MRNA Vaccine
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
GSK, CureVac MRNA Flu Shot Reaches Late-stage Studies
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
